This brand name is authorized in Malta, Poland
The drug SUBINIT contains one active pharmaceutical ingredient (API):
|
1
Sunitinib
UNII LVX8N1UT73 - SUNITINIB MALATE
|
|
Sunitinib inhibits multiple RTKs that are implicated in tumour growth, neoangiogenesis, and metastatic progression of cancer. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01EX01 | Sunitinib | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: MT | Medicines Authority | Identifier(s): MA1217/00101, MA1217/00102, MA1217/00103 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100391322, 100391405, 100391411 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
